CCL2 and medical procedure: Our results revealed that ASC-J9®, a newly developed AR degradation enhancer that could degrade AR in selective cells with few side effects [12–19], could decrease the prostatitis in the NOD mice and suppress the recruitment of T cells to the prostate stromal cells via alteration of the cytokine CCL2 signals.